Austin, Nov. 11, 2024 (GLOBE NEWSWIRE) --“According to S&S Insider, The Neuroscience Market Size was valued at USD 35.3 ...

It had an excellent phase 1b dataset with a very strong treatment effect on the primary endpoint that ... with leading ...

AbbVie today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute ...

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The first is Nuplazid, which was approved in 2016 and remains the only approved treatment for hallucinations and delusions ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

Bobby Allison, founder of racing's "Alabama Gang" and a NASCAR Hall of Famer, died Saturday. He was 86. NASCAR released a statement from Allison's family that said he died at home in Mooresville, ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

2-Year U.S. Treasury Note Continuous Contract $102.734-0.035-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.891-0.117-0.11% 10-Year U.S. Treasury Note Continuous Contract $110.078-0.203 ...